LGM Pharma, a number one supplier of tailor-made API and CDMO companies for the total drug product lifecycle, right now reported robust development in 2022 in each its long-established Lively Pharmaceutical Ingredient (API) division and its new contract growth and manufacturing (CDMO) division. LGM acquired its CDMO division in 2020, with full operational integration completed in late 2021 for industrial manufacturing and for the 2 newly-created CDMO service segments – Analytical Testing Companies (ATS) and Drug Product Analysis & Growth (R&D).
The robust demand for these service choices led to 49 ATS and R&D tasks booked in 2022, attaining 150% of gross sales finances within the first full 12 months of operations for these new service segments. Demand in 2022 additionally remained robust for LGM Pharma’s established API Companies division, with over 300 distinctive APIs delivered and 1700+ imports dealt with for purchasers.
Strong buyer demand fueled robust development and funding within the CDMO division’s service segments, which offer analytical testing; technique growth and validation; formulation growth; medical trial materials manufacturing and testing; stability research; regulatory submissions; industrial manufacturing and extra. The CDMO division works with a number of dosage kinds together with oral stable dosages, oral disintegrating tablets, powders, liquids, suspensions, semi-solids and suppositories.
“The robust begin posted by our CDMO enterprise displays our company-wide dedication to supporting buyer wants with quality-assured, customer-centric methods. These methods are designed to extend velocity and adaptability, cut back provide chain dangers and enhance entry to high-quality drug merchandise and APIs. We established the CDMO division to give attention to the unmet wants of small to mid-size biopharma corporations and are particularly happy with the demonstrated velocity, agility, and adaptability we make use of to satisfy their distinctive wants. We sit up for persevering with robust development in our CDMO division, the place our a number of US-based services and skilled technical employees are well-positioned to assist firms advance their merchandise by means of profitable commercialization.”
dr Prasad Raje, Chief Government Officer of LGM Pharma
In its API sourcing enterprise, LGM takes a bespoke strategy to assembly a consumer’s general aims. By understanding the total life cycle of a product upfront, LGM can tackle their API sourcing wants in a sustainable and scalable manner. Purchasers additionally get entry to a extremely scrutinized and certified community of modern API producers – developed over a long time – which permits LGM to offer purchasers with distinctive companies, equivalent to supplying novel and hard-to-source APIs which are quality-assured and compliant with US rules.
dr Raje continued, “The worth of our customized API sourcing methods for purchasers has by no means been extra obvious than within the present period, with provide chain points remaining a serious problem for drug producers. Our persevering with success in rising this enterprise is constructed on a number of key ideas. First is our ongoing dedication to high quality and steady enchancment in our quality-focused processes and procedures, the place we have now made vital investments over the previous a number of years. One other key success issue is our proactive strategy to working with purchasers on danger mitigation, utilizing ways equivalent to pulling shipments ahead, growing security inventory, proactively addressing attainable delays, and discovering alternate manufacturing sources when wanted. This mix of high quality focus and proactive danger mitigation has earned us the belief and loyalty of a rising buyer base.”
LGM Pharma brings its pharmaceutical clients greater than 100,000 sq. ft of specialised gear, manufacturing and warehouse services in California, Colorado, Florida, Kentucky, and Texas; professional employees with over 100 years of mixed drug growth experience; an unparalleled world community of prequalified CGMP API producers with greater than 6,000 APIs delivered to purchasers within the final three years; a rigorous dedication to high quality that spans each facet of the corporate’s enterprise; and a perception that clients are greatest served as companions, working collaboratively with LGM Pharma to craft individualized frameworks to optimize their tasks.
To study extra about LGM Pharma’s distinctive suite of API sourcing and drug product CDMO companies, request a gathering at [email protected] with firm executives at 2023 DCAT Week, March 20-23, in New York Metropolis.
